Observed arrival · 2026-10-21
SGCB Research Initiative’s AI-Assisted LGMD R4 Repository
Credibility concern recorded. The source reference remains available for verification and correction.
A research-literature hub covering beta-sarcoglycanopathy, including genetics, gene therapy, CRISPR, and proposed cytoprotective peptide concepts.
- For
- Families and researchers following LGMD R4
- Worth noticing
- It labels its modified peptide sequences as unvalidated in-silico concepts, never tested in animals or humans, and not for clinical use.
Field notes
The repository groups material into genetics, therapeutic approaches, contraindications, and literature, with a separate research-radar section naming PubMed, ClinicalTrials.gov, and Google News as sources. It lists technical PDFs and 14 citations, while its charter distinguishes established care from investigational work. The page specifically says its modified peptide sequences are theoretical and have not been tested in animals or humans.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
One card from the complete issue